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Abstract: The administration of drugs to treat ocular disorders still remains a technological challenge in this XXI century. 
Although there is an important arsenal of active molecules useful to treat ocular diseases, ranging from classical compounds 
to biotechnological products, there is not currently any ideal delivery system able to profit all their therapeutic potential. 
Among the intraocular drug delivery systems (IODDS) proposed to overcome some of the most important limitations, 
microsystems and nanosystems have raised high attention. While microsystems are able to offer long-term release after 
intravitreal injection, nanosystems can protect the active compound from external environment (reducing their clearance) and 
direct it to its target tissues. In recent years, some researchers have explored the possibility of combining micro and 
nanosystems in “nanoparticle-in-microparticle (NiMs)” systems or “trojan systems”. This excellent idea is not exempt of 
technological problems, that remains partially unsolved, especially in the case of IODDS. The objective of the present review 
is to show the state of art concerning the design, preparation and characterization of trojan microparticles for drug delivery 
and to remark their potential and limitations as IODDS, one of the most important challenge faced by pharmaceutical 
technology at the moment. 
Keywords: Trojan systems, nanoparticles-in-microparticles (MiMs), ophthalmic drug delivery, posterior segment, intravitreal 
injection, intraocular drug delivery systems (IODDS). 
 
1. INTRODUCTION 
The administration of drugs to treat ocular disorders still 
remains a technological challenge in this XXI century. 
Although there is an important arsenal of active molecules 
useful to treat ocular diseases, ranging from classical 
compounds to biotechnological products, there is not 
currently any ideal delivery system able to profit all their 
therapeutic potential.  
When the target tissue is located in the anterior segment of 
the eye the ocular topical route is preferred. This local 
administration results non-invasive and relatively 
comfortable for patients. However, most of the active 
compounds have low local bioavailability due to the reduced 
contact time on the ocular surface of traditional eye drops 
and to the low inherent corneal permeability of most of the 
active compounds. 
The challenge is still bigger when the target tissue is in the 
back of the eye. Periocular routes, peribulbar, retrobulbar, 
posterior yuxtascleral, subtenon or subconjunctival routes 
(Figure 1), are interesting options. The formulation is 
injected in different zones surrounding the eye globe 
however the drug has to be able to reach itself the intraocular 
tissues by diffusing through the sclera, the choroid and, 
depending on the injection site, also though the aqueous 
humor and vitreous [1, 2].Intraocular administration routes 
involve the direct deposit of the formulation in the proximity 
of the target tissue into the ocular globe, to treat pathologies 
affecting the anterior segment of the eye (intracameral route) 
[3], and also the posterior segment of the eye (intravitreal 
route, subretinal route, etc.) [4] (Figure 1). 
 
 
 
 
 
 
 
 
 
Figure 1. Schematic representation of eye and ocular 
administration routes. 
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Intravitreal injections are preferred in clinic to treat 
vitreoretinal diseases. However, several issues limit their 
utility. When the whole dose is locally deposited, the high 
initial drug concentration achieved might result toxic for the 
retina. However, after that, the vitreous concentration of 
drugs rapidly drops to low values due to different clearance 
mechanisms. Although the elimination of active compounds 
from the vitreous depends on several factors such as size and 
polarity of the molecule, in many cases half-life values of 
only several hours are found [5]. All these events joined to 
the fact that most part of vitreoretinal disorders are chronic 
diseases, make necessary the use of repeated intravitreal 
injections for a successful therapy. Unfortunately, repeated 
intravitreal injections are associated to important adverse 
effects such as cataracts, retinal detachment, haemorraghes, 
risk of infections, among others, due to the injection itself.  
For more information concerning the above-mentioned 
information, researchers are kindly suggested to read several 
recent complete reviews about the subject [2, 6-8]. 
In the case of diseases affecting the posterior segment of the 
eye, several kinds of devices such as implants (>1mm) and 
microsystems (1-1000 μm) have been proposed. These 
intraocular drug delivery systems (IODDS) are able to 
provide sustained delivery of the loaded active compound in 
the vicinity of the target site for long periods of time. In fact, 
several implants are currently used in the clinical practice 
with high acceptance from patients and professionals. 
Concerning to clinical use, microparticulate systems have 
been less explored than implants but offer important 
advantages. For example, they can be injected using the 
conventional needles employed for intraocular 
administration. Depending on the biomaterial used in their 
preparation, microparticles can agglomerate once 
administered, forming an in situ depot, able to release the 
active compound for months. If biodegradable materials are 
employed, the IODDS gradually disappears from the 
injection site once released the active compound. 
Furthermore, as the amount of administered microparticles 
can be easily modified, they are very suitable for 
personalized therapies [6, 7]. Several authors have 
demonstrated the usefulness of microparticles for effective 
delivery of active compounds after intravitreal 
administration [9-11].  
Nanosystems have been also proposed as IODDS. Due to 
their small size (1-1000 nm) and to the possibility of 
presenting different surface nature, they can be designed to 
undergo cell internalization. Furthermore, they can protect 
the active compound form vitreal environment. Numerous 
studies have demonstrated the utility of nanosystems for the 
effective administration of active compounds at retinal level 
[12-16]. 
According to the previously exposed, on one hand, 
microsystems are able to offer long-release after intravitreal 
injection, and on the other hand, nanosystems can protect the 
active compound from external environment, reducing their 
clearance, and directing it to its target tissue. In recent years, 
some researchers have explored the possibility of combining 
micro and nanosystems to create a new generation of drug 
delivery systems with the potential advantages of both. 
These are the named “nanoparticle-in-microparticle (NiMs) 
systems or, more poetically, “trojan systems”.  
The trojan systems can be then defined as microparticles that 
are loaded with nanoparticles, which, in turns, carry the 
active compound. Ideally, once administered, the 
microparticles will slowly release the nanoparticles for long 
periods, protecting the unreleased nanoparticles from 
external environment. Once released, nanoparticles will be 
then directed to the target cells, internalized and will release 
the active compound into the cell (figure 2). This would 
allow maximizing the efficacy of the administered active 
molecule, by minimizing their clearance before reaching the 
target cell.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Schematic representation of trojan microparticles 
delivering nanoparticles close to the retinal and further 
nanoparticles cell internalization. 
This excellent idea is not exempt of technological problems 
that remains partially unsolved at present, such as the 
efficient encapsulation of nanosystems in microparticles, the 
achievement of reproducible microparticle size, release 
patterns of nanosystems from microparticles and of active 
compounds from nanoparticles, etc. It is important to take in 
mind that all this must be achieved by using mild preparation 
techniques in order to preserve the active compound 
integrity, especially if it is a bioengineered compound. 
Furthermore, in the special case of IODDS additional 
limitations such as the use of only extremely well tolerated 
biomaterials for the preparation of the trojan systems and 
also the need of sterilization, makes the design, preparation 
and characterization of trojan systems for intraocular drug 
delivery one of the most important challenge faced by 
pharmaceutical technology at the moment.  
The objective of the present review is to show the state of art 
concerning the design, preparation and characterization of 
trojan microparticles (nanoparticles-in-microparticles, NiMs 
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systems) for drug delivery and to remark their potential and 
limitations as IODDS. 
2. TROJAN MICROPARTICLES. TECNOLOGICAL 
APPROACH 
2.1. Trojan microparticles composition and elaboration 
Several techniques of microencapsulation have been adapted 
to allow the effective entrapment of nanoparticles. In this 
part, the main microencapsulation methods employed to 
prepare trojan systems will be mentioned. 
2.1.1. Emulsion techniques 
Some of the techniques most commonly used to prepare 
trojan microparticles are based on the formation of an 
emulsion and subsequently solvent extraction/evaporation. 
Amiji and collaborators published between 2006 and 2011 
several works showing the benefit of NiMs systems of 
gelatin nanoparticles in poly-caprolactone microparticles for 
oral gene delivery [17-20]. These were some of the pioneer 
works showing the potential benefit of the micro-nano 
combination. They first prepared gelatin nanoparticles by 
desolvation and controlled precipitation using ethanol as 
non-solvent. After preparation, nanoparticles were 
lyophilized and subsequently suspended in water, forming 
the inner aqueous phase of a W/O/W double emulsion to 
prepare the final poly-caprolactone microparticles. Authors 
identified three critical parameters affecting the trojan 
system particle size: concentration of policaprolactone in the 
O-phase, speed of the homogenization to form the W/O/W 
emulsion and, importantly, the amount of nanoparticles 
included in the inner W phase of the double emulsion. 
According to the authors, when the amount of nanoparticles 
in the inner aqueous phase increases, the collision and fusion 
of droplets of this aqueous phase is reduced during the 
primary W/O emulsion, leading to smaller microparticles 
after the W/O/W emulsion [19]. Years later, Lee et al (2013) 
[21] performed a deep analysis of the different technological 
variables affecting the preparation of trojan microparticles by 
W/O/W emulsion. They firstly prepared nanoparticles using 
polycaprolactone as polymer entrapping the drug 
hidrocortisone. Then, these nanoparticles were included as 
solids in the inner aqueous phase of the double emulsion and 
prepared PLGA microparticles, forming a S/W/O/W system. 
These authors paid especial attention on the state of 
nanoparticles, evaluating their incorporation as dry powder 
but also as “slurry mass”. According to the results previously 
described, these authors suggested that the distribution of 
nanoparticles within the primary emulsion influences their 
ultimate destination in the final microparticle. In this study 
they demonstrated that the inclusion of nanoparticles with 
high tendency to agglomerate (“slurry mass”) led to better 
internalization in microparticle structure, while dry 
nanoparticles presented more tendency to locate in the 
vicinity of microparticle surface and even on the 
microparticle surface. This different nanoparticles 
distribution will have a strong influence not only on the 
encapsulation efficiency but also on the release profile. Chen 
et al., (2014) [22] also used the S/W/O/W method to prepare 
PLGA brucine-loaded nanoparticles dispersed in PLGA 
microparticles with the aim to overcome the problem of 
burst release and to prolong the release time. 
Single emulsion has been also used to prepare trojan 
microparticles. For example, Farris et al., (2017) [23] 
initially prepared chitosan nanoparticles including DNA 
plasmid by ion gelation. Nanoparticles were suspended in 
distilled water and the suspension was mixed with a solution 
of zein in ethanol. This hydro-alcoholic media was 
emulsified with an oily external phase (corn oil). After 
solvents evaporation zein microparticles encapsulating 
chitosan/plasmid nanoparticles were recovered.  
Additional novel microencapsulation methods based on 
emulsions formations are also being evaluated to prepare 
trojan systems. For example, Khan et al (2015) [24] used a 
microfluidic system to prepare trojan nanoparticles in two 
semi-continuous steps. They first prepared an O/W 
nanoemulsion containing the active compound (ketoprofen) 
and acrylic monomers. This nanoemulsion was subequently 
emulsified with an aqueous phase containing acrylamide 
monomers and different surfactants. The microdroplets (and 
the nanoemulsion included in them) were hardened by UV-
induced polymerization of the corresponding monomers. 
Guo et al., (2014) [25] prepared calcium phosphate 
nanoparticles loaded with a plasmid encoding two growth 
factors. The nanoparticles were included in microparticles 
prepared by electrospray using a mixture of poly(ethylene 
glycol) (PEG) blended with the copolymer poly(ethylene 
glycol)-poly(Lactide) (PELA). According to authors, 
electrospray techniques offer a low-cost and rapid method to 
obtain particles with high production efficiency. The method 
employed was based on the fact that a strong electric field 
during electro-spraying can break up a jet liquid into a 
continuous stream of finely dispersed droplets. To obtain the 
trojan systems the liquid used was a previously formed 
emulsion formed by an inner aqueous phase of nanoparticles 
suspended in distilled water and an external phase of the 
polymer solubilized in an organic solvent (dimethylformide). 
After the droplet formation, the organic solvent was 
evaporated during flying to the collector. The microparticles 
created were collected in water, centrifuged and finally 
freeze-dried.  
 
2.1.2. Spray drying techniques 
Spray drying is another of the technological approaches 
evaluated to produce trojan microparticles. For example, 
Elbaz et al (2016) [26] prepared several nanoparticulate 
systems containing propolis extract (solid dispersion, 
pluronic nanoparticles and PLGA nanoparticles) within 
chitosan microparticles. The method employed was spray-
drying of a quitosan aqueous solution containing the 
nanoparticles suspension. The idea of authors is that this 
nanoparticles-in-microparticles structure might be able not 
only to control the release of the active and protect it from 
gastrointestinal environment after oral administration, but 
also to increase the propolis extract aqueous solubility. 
Ozeki et al., (2012) [27] developed a spray-drying method 
able to prepare in only one-step nanoparticles in 
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microparticles. To this, authors used a two-solution mixing 
type nozzle, which is able to mix an organic media 
containing components necessary to create the nanoparticles 
and an aqueous media including the microparticles forming 
polymers. This method has several relevant advantages. It 
reduces the manipulation of nanoparticles as intermediate 
products and also interestingly it allows the preparation of 
the trojan systems without any solvent or surfactant. At the 
moment this technique has been used to prepare 
nanoparticulate pure drugs or empty polymeric nanoparticles 
(ethylcellulose), both in mannitol microparticles. Although 
none of these prototypes can be considered “trojan systems” 
as described in this review, this technique could be used in 
the future to prepare them.  
Although, as mentioned before, in most of the cases trojan 
microparticles are being explored to protect the active 
compound from external environment and to prolong its 
release, some alternative interesting strategies focused on 
targeting have been also proposed. For example, Deng et al., 
(2014) [28] prepared cationic mesoporous silica 
nanoparticles loaded by electrostatic interaction with 
ovoalbumin (as model antigen). The nanoparticles were then 
included in an aqueous solution of different sugars 
(trehalose, mannitol) and dextran that was finally freeze 
dried to obtain the microparticles. In this case the objective 
was not to extend the delivery of the active compound, but to 
create microcarriers able to meet all physical parameters 
required for intradermal powder injection (particle size big 
enough to have good flowability and to reduce the risk of 
clumping in the syringe). Once injected, the sugar-based 
microparticles dissolves in the subcutaneous media, rapidly 
releasing all nanoparticles in a high concentrated sugar 
matrix, which in turns offers additional protection to the 
released protein. Tewes et al., (2014) [29] used a spray-
drying method to prepare polyethylene glycol 
(PEG)/hydroxypropyl-beta-cyclodextrin and ammonium 
carbonate microparticles containing superparamagnetic iron 
oxide nanoparticles. The rational of this design was the 
preparation of particles able to reach deep lung alveolar 
regions with the external direction of a magnetic field, 
avoiding all aggregation typically occurring to nanoparticles 
alone after inhalation. The microparticles size was optimized 
by modifying the atomization procedure to reach the 1-5 µm 
range. Unfortunately, no drug loading was performed in the 
work, however, authors claimed that if the nanoparticles 
were loaded with active compounds the trojan systems 
generated could be very useful in the local treatment of lung 
diseases such as cancer nodules or bacterial infectious foci. 
In this same line, Bakhtiary et al., (2017) [30] also used 
microparticles with optimal size, flowability and 
aerodynamic behavior, able to reach the desired part of lung 
after inhalation. Once deposited, microparticles, made of 
mannitol by spray-drying, rapidly released the solid lipid 
nanoparticles embodied which were loaded with an 
anticancer drug (erlotinib). Schuze et al., (2018)[31] also 
used the spray drying technique to prepare a nanoparticles-
in-microparticles inhalatory gene delivery system. The trojan 
systems were generated by combination of 
polyethyleneimine (PEI) based polyplexes and 
lipopolyplexes into polyvinyl alcohol (PVA) microparticles. 
The previously prepared nanosystems were suspended in 
PVA solution and directly spray-dried without any 
stabilizing agent. Microparticles resulted in the 3-5 µm range 
and spherical. Due to the hydrophilic nature of the polymer 
employed to prepare the microparticles, once in contact with 
aqueous media the trojan system rapidly disintegrates 
releasing the nanosystems. 
2.1.3. Gelation techniques 
In an interesting work, Pinkerton et al., (2013) [32] prepared 
trojan microparticles by gelation. Authors first produced 
polystyrene nanoparticles that were then included in 
polyethylene glycol (PEG) microgels obtained by different 
crosslinking methods. This last step was achieved by 
inclusion of nanoparticles in a PEG solution that was then 
emulsified with silicon oil. UV radical polymerization and 
Michael addition polymerization reaction were proposed as 
possible techniques to obtain the final microgels. This 
further was the selected, so no reduction of fluorescence was 
obtained when a fluorescent marker was included in 
nanoparticles, demonstrating that Michael reaction 
maintained the integrity of the encapsulated compound, 
while UV exposure promoted the degradation of 
encapsulated compound by radical attack. Particles were 
prepared in a range size suitable for effective lung targeting 
(drug delivery and imaging) after intravenous administration 
via venous filtration pathway. Once intravenously injected 
microparticles are trapped in lung tissues the hydrogel is 
progressively degraded to release the nanoparticles. In a 
different approach, ionic gelation was used by Garrati et al 
(2014) [33] to prepare alginate microparticles containing 
chitosan nanoparticles. Nanoparticles were prepared by 
precipitation/coacervation method containing amaranth red 
as model loaded molecule. Chitosan nanoparticles were 
included in an alginate solution that was forced to pass 
trough a vibrating nozzle to create microdrops. These 
microdrops were collected in a calcium chloride solution to 
promote the ionic crosslinking of alginate forming then the 
microparticles. Trojan microparticles were finally spray-
dried. Authors considered as main critical technological 
point the preparation of an homogeneous suspension of 
nanoparticles in alginate solution and also the 
nanoparticles/alginate ratio. It was observed that when high 
concentrations on nanoparticles were employed immediate 
precipitation occurred, so only nanoparticles suspension 
bellow 0.2% resulted adequate. Subsequently, authors also 
demonstrated that a high alginate concentration was 
necessary to obtain spherical trojan nanoparticles. 
Interestingly, special attention was also paid in minimizing 
the “drug” release from nanoparticles in the alginate 
solution. To this, several parameters such as adjusting pH 
and including a non-ionic surfactant (Tween 80) resulted 
useful. Effectively, depending on the microencapsulation 
procedure used to prepare the trojan systems and on the 
physicochemical characteristics of the active compound, in 
some cases the release of loaded active compound from the 
nanoparticles during the microencapsulation process must be 
considered. 
2.2 Trojan microparticles characterization 
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Some techniques generally used to describe simple 
microparticles can be also used in the case of trojan 
microparticles, such as main particle size and particle size 
distribution measurements by dynamic light scattering 
techniques or microscopy, surface morphology evaluation by 
scanning electronic microscopy, etc. However other 
techniques such as quantification of loaded active compound 
in the trojan system or in vitro release profiles studies need 
to be modified in order to better characterize the new 
systems. Furthermore, additional techniques rarely employed 
for microparticles characterization became relevant in the 
case of trojan systems. 
2.2.1 Active compound encapsulation efficiency in Trojan 
microparticles 
The quantification of the active compound loaded in the 
trojan systems generally must be carried out in several steps. 
In the first one the nanoparticles need to be extracted from 
the polymeric matrix forming the microparticle. The most 
used method to aim this goal is to dissolve the trojan 
microparticles in a solvent in which nanoparticles are 
insoluble. After that, the recovery of nanoparticles is 
performed by extraction with a suitable solvent. Finally, the 
media containing the extracted nanoparticles has to be 
treated to separate and quantify the active compound. All 
these steps can compromise the stability of the active 
compound, especially if it is a bioengineered product 
(oligonucleotides, peptides, proteins), so bioactivity studies 
are required at the end of the study. Amiji and co-workers 
used a combination of methylene chloride and distilled water 
to dissolve polycaprolactone, polymer used to prepare the 
trojan microparticles, and extract the embodied gelatin 
nanoparticles, respectively. Further treatment consisting on 
dissolving gelatin by using proteases and subsequent 
fluorescent quantitation assays were performed to determine 
the amount of plasmid DNA initially loaded in the trojan 
microparticles [17]. In the same sense, Guo et al., (2014) 
[25] dissolved the PEG-PELA trojan microparticles in 
methylene chloride. The calcium phosphate nanoparticles 
included in them were extracted several times in aqueous 
media. After that, the plasmid DNA loaded in nanoparticles 
was quantified by fluorescence measurement.  
In some cases it is also possible to direct degrade 
microparticles and loaded nanoparticles in the same step. For 
example, Garrati et al (2014) [33] disrupted their whole 
trojan systems (alginate microparticles containing chitosan 
nanoparticles) by dissolving them in a sodium bicarbonate 
and tri-basic sodium acetate at pH 8. 
Other authors have opted to perform more simple methods. 
For example, Khan et al., (2015) [24] simply incubated the 
trojan microparticles in release media for 48 hours to, 
according to authors, complete extract the active compound 
(ketoprofen) included in the trojan systems (composed by 
nanoparticles prepared with acrylic polymers and then 
microencapsulated in acrylamide polymer). However, 
additional studies demonstrated that part of the drug could 
not be extracted at these conditions. So, in general, it does 
not seem an appropriated method to determine the active 
compound encapsulation efficiency. 
When the active compound is radiolabeled, direct 
measurement can obviously be performed [23] without need 
of extraction procedures. 
Some authors only evaluate the drug loading efficiency on 
initial nanoparticles without any further evaluation of the 
trojan system in this sense, assuming that no waist of 
material nor drug degradation occur during the 
microencapsulation procedure [26, 30]. However, as general 
rule, these encapsulation efficiency data might be taking into 
account only as approximated values. 
2.2.2. In vitro release profile of the loaded active 
compound from trojan microparticle 
When performing in vitro release studies from classical 
microparticles, typically a known amount of them are placed 
in a tube filled with release media at controlled temperature 
and shaking. Supernatant samples are periodically extracted 
and measured to determine the concentration of released 
active compound. However, when trojan systems are used, 
the study of the release profiles becomes more complicated. 
On one hand, some authors simply evaluate the amount of 
active compound released form the trojan system, with some 
modifications from the basic methodology. For example, 
Amiji and co-workers used a release media containing 
proteases to ensure nanoparticles (prepared with gelatin) 
dissolution once released, and the plasmid DNA 
incorporated in them was directly measured in the 
supernatant by fluorescence measurements [17]. Using this 
methodology both, the nude active compound released from 
the trojan systems and the active compound included in the 
released nanoparticles are jointly quantified. Other authors 
such as Khan et al., (2005), Chen et al (2014) or Elbaz et al 
(2016) [22, 24, 26] used dialysis bags or dialysis tubes to 
separate the trojan system and nanoparticles delivered from 
the released active compound that can be then easily 
quantified.  
However, a more complete characterization of the trojan 
system can be achieved if, as previous steps, the method is 
modified to determine the amount of nanoparticles released 
from the trojan system. With this aim, several authors have 
explored some astute alternatives. For example, Khan et al 
(2015) [24] incubated the trojan system in release media for 
two hours and then they observed the supernatant under 
transmission electronic microscopy (TEM) to determine the 
presence of nanoparticles. No quantification studies were 
able with this technique. In this sense, Guo et al (2014) [25] 
evaluated the in vitro plasmid DNA release from the Trojan 
nanosystems created (calcium phosphate nanoparticles in 
PEG-PELA microparticles) in two parallel studies. In one of 
them microparticles were incubated in release media, the 
supernatant was taken at fixed time points, and the released 
nanoparticles were determined by electrophoresis. In a 
second set of experiments the release media was used to 
quantify the total released plasmid DNA. 
2.2.3. Imagine techniques and other methods useful for 
trojan microparticles characterization 
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Since it is so easy to prepare nanoparticles including 
fluorescent markers, the use of fluorescent microscopy (and 
even better confocal microscopy) becomes a very useful tool 
to determine the distribution of nanoparticles into the 
polymeric microparticle. [21, 24, 28]. The direct 
visualization of loaded compounds into the polymeric matrix 
has been sometimes used to characterize classical 
microparticles [10]. This technique offers very useful 
information. It confirms the trojan morphology and it can 
result a very interesting tool during the optimization of the 
microencapsulation process. Additionally, it allows the 
prediction of the in vivo behavior (whether nanoparticles will 
remain in the polymeric matrix structure or will rapidly 
scape from it). This technique was used by Lee et al., (2013) 
[21] to observe the different distribution of polycaprolactone 
nanoparticles in PLGA microparticles when they were 
incorporated as dry powder in a S/W/O/W emulsion or as 
“slurry mass”. The confocal observation of trojan systems is 
even more informative when it is possible to simultaneously 
observe both, the nanoparticles and the microparticle matrix. 
With this idea, Garrati et al (2014) [33] used two label 
molecules to identify chitosan nanoparticles (fluorescein) 
inside alginate microparticles (rhodamine). Using this 
technique authors were able to observe a homogeneous 
distribution of nanoparticles within the microparticle 
polymeric matrix. 
The distribution of nanoparticles within the trojan 
microparticles can be also evaluated by scanning electronic 
microscopy (SEM) evaluation of cryo-fractured 
microparticles [21, 24]  
Bhavsar et al., 2007 [17] used SEM studies to determine 
whether the trojan systems created (poylcaprolactone 
microparticles included gelatin nanoparticles entrapping 
plasmid DNA) were able to protect the nanoparticles from 
external environment. They incubated the trojan systems in a 
media including proteases (able to digest gelatin) and 
observed no degradation of the system after a 2h-incubation. 
Incubation of trojan microparticles in different media 
mimicking biological conditions can also result very useful. 
For example, Farris et al., (2017) [23] prepared chitosan 
nanoparticles included in zein microparticles. Zein is a corn 
protein able to protect nanoparticles for stomach media after 
oral administration. To confirm that, they incubated the 
microparticles at pH 1.2 in a media containing pepsin for 15 
min a 37ºC and after that they evaluated the transfection 
efficiency of the system in comparison with untreated 
samples. They observed the same transfection capacity in 
both cases demonstrating the total protection of 
nanoparticles from external environment. Similarly, Guo et 
al., (2014) [25] demonstrated the protective effect of the 
trojan system created (calcium phosphate nanoparticles 
loaded with plasmid DNA and included in PEG-PELA 
microparticles) by quantification of plasmid DNA after 
subjecting them to DNase I digestion for 48 hours. 
 
3. TROJAN MICROPARTICLES POTENTIAL FOR 
THE TREATMENT OF OCULAR DISEASES.  
As it has been pointed out in the text, although nanoparticles 
alone offer interesting advantages in targeting and cell 
internalization, for some administration routes microparticles 
are preferred. As mentioned before, for example in the case of 
transdermal administration, pulmonary administration or venous 
filtration pathway to the lung. In these cases nanoparticles alone 
are too small to reach the target tissue. They can agglomerate in 
the injection site, they cannot be deposited in the desired part of 
the affected organ or they cannot be retained by filtration. In 
general, nanoparticles are difficult to manipulate, not only in its 
dry form but also as suspension, so they can undergo hydrolysis, 
sedimentation, etc. [34]. 
When treating diseases affecting the back of the eye the size of 
particles also strongly influences their behavior and location 
after injection. Microparticles generally tend to deposit 
(aggregated or not, depending on the nature of the biopolymer 
used) not perturbing the patients’ vision and are retained in the 
ocular cavity. Only in absence of crystalline they have been 
located in the anterior chamber [35]. On the contrary, when a 
nanoparticles suspension is injected in the vitreous their 
distribution seems to strongly depend on the surface 
characteristics [36]. For example, cationic nanosystems (those 
more promising for gene delivery) can be retained in the 
vitreous by electrostatic interaction with anionic intravitreal 
collagen fibrins dispersed in the whole cavity. On the contrary, 
anionic nanoparticles can be cleared from the vitreous diffusing 
to retinal layers and other ocular tissues [37]. Although the 
toxicity of nanoparticles in the vitreous is not well evaluated in 
the scientific literature, it seems that a massive presence of 
nanoparticles in the vitreous could activate hyalocytes, the 
sentinel immune cells of the vitreous, depending on the 
nanoparticles chemical nature [38]. Some studies have 
demonstrated that the size of particles can affect also their 
distribution after periocular administration. For example, 
Amrite et al (2005) [39] observed that while microparticles 
could be retained in the site of injection after subconjunctival 
injection for several weeks, nanoparticles (20 and 200 nm) tend 
to be rapidly cleared from subconjunctival space after injection 
due to systemic and lymphatic circulation. 
The combination of nano- and microsystems in trojan 
microparticles for intraocular delivery might offer several 
benefits. On one hand the facility of manipulation and the more 
controlled behavior once injected in the vitreous, characteristics 
of microparticles, in addition to the tuning of sustained release 
for long periods. On the other hand, the embodied nanoparticles 
would offer all the advantages in terms of active compound 
protection and cell internalization.  
Gómez-Gaete et al (2008) [34] developed an interesting work 
proposing PLGA (75:25) nanoparticles loaded with 
dexamethasone acetate included in microparticles composed by 
a combination of a phospholipid (1,2-Dipalmitoil-sn-Glycerol-
3-phosphocholine -DPPC-) with hyaluronic acid (HA). 
Dexamethasone is a corticoid anti-inflammatory drug useful in 
the treatment of several posterior segment eye diseases, such as 
uveitis, proliferative vitreoretinopathy or subretinal 
neovascularization among others [40]. The use of IODDS is 
being explored to reduce the number of applications and the 
side effects associated to massive presence of the corticoid in 
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the eye such as cataracts. Authors prepared dexamethasone 
loaded PLGA nanoparticles by an O/W solvent emulsion-
evaporation technique. After hardening of nanoparticles, 
separation of dexamethasone crystals by filtration and from 
soluble dexamethasone by ultacentrifugation, fresh (non freeze-
dried) nanoparticles were suspended in water. In parallel, 
DPPC/HA hydro-alcoholic solution was prepared. After that, 
the polymer solution and the nanoparticle suspension were 
pumped using a two digital gear pump connected to an acetal 
helix that performed the mixture on the two media before spray 
drying. As mentioned before, it is necessary to guarantee that 
the loaded drug remains in the nanoparticles during the 
microparticles preparation. That is why authors decided to 
separately pump the nanoparticle suspension and the hydro-
alcoholic solution and then mix the two liquids just before the 
spray, reducing the contact time between nanoparticles and 
ethanol that might promote the partial solution of 
dexamethasone. The final trojan systems created were 
characterized using some of the techniques already exposed 
before. Different concentrations of nanoparticles (2.2-3 g/L) 
during the freeze-drying step were tested to optimize the trojan 
microparticles mean particle size. Analysis of the different 
batches prepared showed non-substantial changes on particle 
mean size and particle size distribution, with values around 1 
µm for D10 and 16 µm for D90, neither on the production yield (around 33%). Similarly, SEM and confocal observations 
demonstrated that the so prepared microparticles resulted in a 
hollow shell structure, both in absence and in presence of 
nanoparticles. In previous studies authors demonstrated that 
hyaluronic acid was the responsible for this conformation. 
Interestingly, the presence of nanoparticles influenced the 
microparticles surface, changing from a smooth aspect to a 
roughness one, due to the clear presence of nanoparticles on it. 
Confocal images also demonstrated that nanoparticles resulted 
homogenously distributed within the polymeric matrix and in 
general remained as individual entities, no matters the 
concentration used during the microparticles formation. 
However exhaustive studies of the nanoparticle size after spray-
drying showed a significant increment in the mean size values 
of nanoparticles (from 200 nm to 230 nm) and a broad particle 
size distribution, indicating some extent of nanoparticle 
irreversible aggregation during microparticles formation. The 
inclusion of dexamethasone-loaded nanoparticles in the trojan 
systems promoted a change in its in vitro release. When free 
nanoparticles were tested the release of the 90% of 
dexamethasone release from them was observed in the first 4 
hours and the remained 10% was released before 72 hours. For 
trojan systems a more sustained and prolonged release was 
obtained with a 80% of drug content released after 72h of in 
vitro study. However, in the case of trojan systems, interestingly 
a more important burst effect was observed when compared 
with free nanoparticles dexamethasone in vitro release, in spite 
of the higher specific surface offered by unprotected 
nanoparticles. This fact was explained as consequence of partial 
leakage of the active compound from nanoparticles to 
microparticles matrix during trojan system formation, 
demonstrating that even having all the possible cautions, this 
fact has to be always taken into account. Unfortunately authors 
have not published at the moment any in vivo study to confirm 
the real potential of the interesting trojan systems proposed, 
however, they claimed that  “the in situ release of drug loaded 
nanoparticles should favor their internalization within retinal 
pigmented epithelial cells and might therefore increase the drug 
efficacy”. 
Bevacizumab in a full-length antibody with anti-VEGF 
(vascular endothelial growth factor) activity. It was 
originally developed for the treatment of several cancer 
diseases (colorectal, lung or brain) but it is also used in 
ophthalmology to treat neovascularization retinal diseases 
such as wet age-related macular degeneration (AMD), 
characterized by an abnormal blood vessel growth in the 
macula. The current treatment of wet AMD with 
bevacizumab is based on a intravitreal monthly injection of 
the protein solution. This is not only extremely 
uncomfortable and dangerous for patients but also results 
very expensive. That is why several research groups are 
currently investigating the use of IODDS to overcome all 
these limitations [8]. Yandrapu et al (2013) [41] elaborated 
bevacizumab-loaded nanoparticles using poly lactic acid 
(PLA) (1.0 dL/g). As first step, plain PLA nanoparticles 
were prepared using the O/W solvent extraction/evaporation 
method. After isolation, PLA nanoparticles were 
subsequently freeze-dried in a bevacizumab solution to 
promote the protein adsorption onto the nanoparticles 
surface. The so prepared Bevacizumab-loaded nanoparticles 
(2.5 mg protein/500 mg PLA; final mean particle size 265 
nm) were then included in porous PLGA (50:50; 0.67 dL/g) 
microparticles elaborated by supercritical infusion and 
pressure quench technology. To this, plain PLGA 
microparticles (around 1.6 µm) were prepared also using the 
O/W solvent extraction/evaporation method. Then a mixture 
of bevacizumab-loaded PLA nanoparticles and PLGA plain 
microparticles was prepared. The mixture was placed in a 
high pressure vessel and was exposed to supercritical CO2. At these conditions amorphous PLGA enables the diffusion 
of CO2 into its polymeric network. Supercritical CO2 acts as a plasticizer able to alter the polymeric network and increase 
the chain mobility. Upon depressurization CO2 rapidly 
expands generating pores in the microparticles matrix and 
increasing its size x7. As nanoparticles are prepared with 
crystalline PLA, they do not undergo all this process 
remaining unaltered, and simply diffuse through the PLGA 
porous matrix to finally locate inside the microparticle and to 
form then the final trojan system.  
As part of the optimization study, several mixtures of 
bevacizumab-loaded PLA nanoparticles and PLGA plain 
microparticles were evaluated at different nano/micro 
proportions (5/95-25/75). Differences were mainly observed 
in the in vitro release profile. When high percentage of 
nanoparticles was include in microparticles (25%) an intense 
burst effect was observed, with a 52% of total loaded protein 
released within the first day. After that, a sustained release 
was observed and the 75% of the active content was released 
at day 21 of the release assay. On the contrary, when low 
proportions of nanoparticles were employed (5-20%), the 
burst effect was progressively reduced to 21-27% and the in 
vitro release was extended with 67-81% of release during 4 
months. According to this, the trojan system containing 10% 
of nanoparticles and 90% of microparticles was selected for 
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in vivo studies. It is interesting to remark that in this 
nanoparticle-in-microparticle approach, the use of 
nanoparticles is not focused on their cell internalization 
properties neither on their ability to protect the active 
compound from the external environment, so once the 
nanoparticle is released from the porous microparticles, the 
adsorbed protein is rapidly released. The use of nanoparticles 
in this case simply ensures the progressive release of the 
compound. In fact, when additional studies were performed 
including directly a bevacizumab solution, in absence of 
nanoparticles, to the PLGA microparticles prior to 
porosification process, the resulting loaded microparticles 
were unable to efficiently control the protein release, 
extending it only for 7 days. Several techniques such as size 
exclusion chromatography, gel electrophoresis, circular 
dichroism and fluorescence spectroscopy were used to 
confirm the stability of bevacizumab after 
microencapsulation and release. SEM pictures allowed the 
direct observation of nanoparticles inside open PLGA 
microparticle’ porous. This disposition was also confirmed 
by confocal microscopy observation. To this, authors 
prepared trojan microparticles using nile red and 6-coumarin 
to label PLA nanoparticles and PLGA microparticles 
respectively. In vivo studies were performed in healthy rats 
by intravitreal injection of 5 μL of microparticle suspension 
(30% w/v; 7.2 μg of bevacizumab). Control studies were 
performed by the injection of the same amount of protein in 
solution. In both cases, a third of the protein injected was 
fluorescently marked with Alexa Fluor 488. This staining 
allowed the in vivo non-invasive observation of the protein 
distribution in animal’ eyes by fluorophotometry. While 
control eyes lost their fluorescent signal two weeks after 
administration, bevacizumab was still present two months 
after injection in eyes treated with the trojan microparticles. 
Two months post-dosing, eyes were enucleated and 
bevacizumab was detected by ELISA in vitreous, retina and 
choroid-RPE, but only in eyes treated with microspheres. All 
these results confirmed the high potential of the new 
methodology proposed for microencapsulation of active 
proteins system for vitreoretinal diseases. 
Elsaid et al., (2016) [42] prepared “trojan” microparticles 
loaded with ranibizumab, an antibody fragment that binds all 
VEGF isoforms, having then antiangiogenic activity. They 
choose chitosan and N-acetyl-cys-chitosan as biomaterials to 
prepare the nanoparticles. Although this biocompatible 
polymer is not yet accepted by regulatory agencies for 
intraocular administration, there is already a topical 
formulation in the market including N-acetyl-cys-chitosan 
(Lacrimera® eye drops, Croma-Pharma) as lubricant for 
treatment of dry eye syndrome [43]. Chitosan nanoparticles 
can be prepared by different methods, being the ionotropic 
gelation the most employed. This method uses mild 
conditions and allows the formation of chitosan 
nanostructures alone or in association with other polymers 
such as hyaluronic acid, also used in this work. Interestingly, 
chitosan has demonstrated to have antiangiogenic activity 
itself, further improved by the presence of cysteine 
molecules in N-acetyl-cys-chitosan. This chitosan derivative 
offers, in addition, a better interaction with ranibizumab, and 
a more sustained release, due to the formation of disulfide 
bonds with thiol groups of the protein. Authors prepared 
ranibizumab-loaded chitosan (Mw < 400,000 g/mol) 
nanoparticles (17-350 nm) using plain chitosan, chitosan 
combined with hyaluronic acid or N-acetyl-Cys-Chitosan. 
After that, nanoparticles were included in PLGA (85:15; Mw 
149,000 g/mol) microparticles prepared by W/O/W double 
emulsion and solvent extraction/evaporation method. 
Ramibizumab-loaded nanoparticles were suspended in water 
forming the inner aqueous phase. Furthermore, plain 
nanoparticles were also included at the same concentration in 
the outer aqueous phase. This astute strategy prevented the 
formation of a concentration gradient able to act as driving 
force for nanoparticles diffusion, jeopardizing their 
entrapment. The trojan microparticles created were evaluated 
in terms of Z potential and particle size using laser 
diffraction techniques and external morphology by SEM. 
Trojan microparticles resulted in the range of 3-6 µm for all 
batches, suitable for intravitreal injection. In the case of 
trojan systems prepared with N-acetyl-Cys-chitosan 
significant lower size values were observed. According to 
authors, this phenomenon could be explained by an 
increased osmotic pressure inside the PLGA matrix 
promoted in presence of the chitosan derivative nanoparticles 
that might prevent the inward diffusion of water molecules 
during microparticles maduration. SEM pictures revealed the 
presence of chitosan nanoparticles on the trojan 
microparticles surface. No confocal studies were performed 
to confirm the nanoparticles distribution on the PLGA 
matrix. All trojan systems proposed resulted well tolerated 
according to mitochondrial activity of ARPE-19 cells 
(human retinal pigment epithelial cells) and HUVEC (human 
vascular endothelial cells) after 24 hours exposition to 
particles concentration from 0.5 to 10000 µg/mL. The 
antiangiogenic activity of ranibizumab released from trojan 
microparticles was evaluated by the analysis of the inhibition 
of HUVEC migration, previously stimulated with VEGF. 
Native ranibizumab, used as control, reduced the cell 
migration 5-folds, similarly to the released protein from the 
different trojan prototypes proposed, ensuring that the 
manipulation of ranibizumab during nanoparticle and 
microparticles formation did not affect its activity. In the 
case of trojan microparticles containing N-acetyl-cys-
chitosan, a slightly decrease of the VEGF-induced migration 
was even observed, probably due to the formation of 
secondary disulfide bonds between the polymer and the 
growth factor. Additionally, the antiangiogenic effect of 
chitosan, hyaluronic/chitosan loaded with ranibizumab or 
unloaded was measured by the capillary-like tube formation 
study. Sadly, no tube length inhibition studies were 
performed using the trojan systems. In any case, authors 
demonstrated that the systems created might be considered 
interesting platforms for the delivery of active anti-VEGF 
proteins after intravitreal administration.  
CONCLUSION 
Nowadays we are experiencing not only a raise of the life 
expectancy but also an increase of quality of life of aged 
population. As most of the vitreoretinal ocular diseases are 
age-related it is mandatory to offer more effective treatments 
that those currently in clinical practice. In this sense, the 
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future of IODDS is promising. Among them, the use of 
nanoparticles-in-microparticle systems will have special 
relevance in the near future. The use of trojan microparticles 
will drastically improve the effectiveness at ocular level of 
already existent active compounds. Their utility to 
administrate bioengineered products is undeniable. 
Furthermore, it will help to reduce local side effects also 
appearing with small molecular weight drugs, such as the 
reduction of adverse effects in the lens associated to the 
intravitreal administration of corticoids anti-inflammatory 
drugs. 
From a technological point of view, the use of trojan systems 
opens also the door to new co-delivery systems and might be of 
high utility to tailor the release profiles by combination of fast 
and slow releases and by reducing or increasing the burst effect 
according to the specific needs of each pathology/patient etc. 
The formation and proper characterization of IODDS based on 
trojan systems is not exempt of problems. As pointed out in this 
review, it is important to ensure that the loaded dose of active 
compound remains in the nanoparticle structure during the 
microencapsulation process and ideally nanoparticles 
aggregation during this process might be avoided. Furthermore, 
as far as we have found in literature, no studies concerning the 
sterilization of trojan systems have been performed yet.  
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